Ksenia M. Yegodayev

MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer

Manu Prasad, Jonathan Zorea, Sankar Jagadeeshan et al. · Journal for ImmunoTherapy of Cancer · 2022 · 66 citations · Full text

Repression of AXL expression by AP-1/JNK blockage overcomes resistance to PI3Ka therapy

Mai Badarni, Manu Prasad, Noa Balaban et al. · JCI Insight · 2019 · 65 citations · Full text

Ap-1/jnk Blockage, Apoptosis, Cell Death +23

TGF-Beta-Activated Cancer-Associated Fibroblasts Limit Cetuximab Efficacy in Preclinical Models of Head and Neck Cancer

Ksenia M. Yegodayev, Ofra Novoplansky, Artemiy Golden et al. · Cancers · 2020 · 54 citations · Full text

MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer

Ofra Novoplansky, Matthew G. Fury, Manu Prasad et al. · International Journal of Cancer · 2019 · 30 citations · Full text

Activation of the <scp>EGFR</scp> / <scp>PI3K</scp> / <scp>AKT</scp> pathway limits the efficacy of trametinib treatment in head and neck cancer

Ofra Novoplansky, Avital Beeri Shnerb, Divyasree Marripati et al. · Molecular Oncology · 2023 · 28 citations · Full text